
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
ข้อมูลล่าสุด
US$26.62
+US$0.81 · +3.14%
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
ราคาปิดก่อนหน้า
US$26.62
+US$0.81 · +3.14%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
ช่วงราคารายวัน
ปัจจุบัน US$26.62
ช่วง 52 สัปดาห์
ปัจจุบัน US$26.62
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ถือ
มูลค่า
83
มูลค่าน่าสนใจมาก
ความเชื่อมั่น
64
เชิงบวก
ความเสี่ยง
57
ความเสี่ยงค่อนข้างสูง
โมเมนตัม
26
กำลังอ่อนตัว
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
ช่วงราคารายวัน
ปัจจุบัน US$26.62
ช่วง 52 สัปดาห์
ปัจจุบัน US$26.62
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$21.25
โอกาสปรับลง 20.17%การกระจายเงินสดแบบแยกส่วนประจำปีต่อหุ้น
US$0.30
2010 ทั้งปี0.0% เนื่องจาก 2009
US$0.30
2,009
US$0.30
2,010
| รายการ | วันจ่ายเงินปันผล | รายละเอียด | วันกำหนดรายชื่อ | วันจ่ายเงิน |
|---|---|---|---|---|
เงินปันผล | 11 มิ.ย. 2553 | US$0.30Annual | — | 30 มิ.ย. 2553 |
เงินปันผล | 11 มิ.ย. 2552 | US$0.30Annual | — | 30 มิ.ย. 2552 |
ขึ้นเครื่องหมาย XD 11 มิ.ย. 2553
US$0.30
Annual
วันจ่ายเงิน 30 มิ.ย. 2553
ขึ้นเครื่องหมาย XD 11 มิ.ย. 2552
US$0.30
Annual
วันจ่ายเงิน 30 มิ.ย. 2552
กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
Avantis U.S. Small Cap Value ETFAVUV34.66M0.11%30.85B USD0.25%US$119.64-0.41%
Vanguard Morningstar Total Stock Market ETFVTI23.78M0.00%2.3T USD0.03%US$381.94+0.63%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV22.22M0.08%26.81B USD0.33%US$37.95-0.39%
iShares Russell 2000 ETFIWM22.03M0.03%78.74B USD0.19%US$278.94+0.49%
Dimensional - US Targeted Value ETFDFAT13.7M0.05%30.12B USD0.33%US$67.27-0.43%
Vanguard Extended Market ETFVXF8.92M0.01%95.4B USD0.05%US$235+0.80%
Dimensional - US Small Cap ETFDFAS8.63M0.03%33.87B USD0.31%US$78.35+0.32%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM7.48M0.05%15.84B USD0.03%US$53.45+0.17%
Avantis U.S. Small Cap Value ETFAVUV
Vanguard Morningstar Total Stock Market ETFVTI
U.S. Small Cap Value Portfolio ETF Class SharesDFSV
iShares Russell 2000 ETFIWM
Dimensional - US Targeted Value ETFDFAT
Vanguard Extended Market ETFVXF
Dimensional - US Small Cap ETFDFAS
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSMเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน